Document is current
Any future updates will be listed below
-
Authors
Zarnegar, Behdad
Carow, Berit
Eriksson, Jens
Spennare, Eva
Öhlund, Pontus
Akpinar, Eray
Bringeland, Emelie
Osterman, Ingrid Lekberg
Lundqvist, Lena
Antti, Johanna
Handin, Niklas
Helgesson, Per-Henrik
Bankefors, Johan
Lövgren Bengtsson, Karin
Sellin, Mikael E.
Palm, Anna-Karin E.
Stertman, Linda
Lunderius Andersson, Carolina
-
Funding
Funding for this research was provided by:
Novavax AB (N/A)
Novavax AB (N/A)
Novavax AB (N/A)
Novavax AB (N/A)
Novavax AB (N/A)
Novavax AB (N/A)
Novavax AB (N/A)
Novavax AB (N/A)
Novavax AB (N/A)
Novavax AB (N/A)
Novavax AB (N/A)
Novavax AB (N/A)
Novavax AB (N/A)
Novavax AB (N/A)
Novavax AB (N/A)
Novavax AB (N/A)
Novavax AB (N/A)
Novavax AB (N/A)
- License Information
-
More Information
Article History
Received: 30 April 2025
Accepted: 24 July 2025
First Online: 5 August 2025
Competing interests
: B.Z., B.C., E.S., P.Ö., E.A., I.L.O., L.L., J.A., P.H., J.B., K.L.B., A.E.P., L.S. and C.L.A. are current or former employees of Novavax AB. E.B. and N.H. were contractors to Novavax AB at the time of manuscript preparation. B.Z., B.C., P.Ö., E.A., I.L.O., L.L., J.A., P.H., J.B., K.L.B., A.E.P. and L.S. are shareholders and/or optionees of Novavax, Inc. J.E. and M.E.S. have no competing interests to declare.
